It is a huge day for Portola Pharmaceuticals (PTLA) as the FDA is set to decide on the company’s New Drug Application (NDA) for andexanet alfa. As I have said in earlier articles. andexant alfa is the key value driver for PTLA. In fact, most of PTLA’s fair value of $75 is due to the drug (valued at $67.50). An approval today will significantly boost PTLA shares, which have been struggling since the start of this year. An approval could also PTLA an attractive takeover target.